Drug Delivery Vehicles

Even though a number of liposomal chemotherapeutic drug formulations have been licenced for cancer treatment, increased Drug Delivery through these liposomes is primarily achieved through passive methods, such as improved permeability and retention. Antibodies Immunoliposomes with the aim of cell-specific targeted medication delivery are in different stages of development. The high molecular weight and negatively charged of siRNA duplexes provide significant obstacles to intracellular distribution and efficient cellular uptake, which are essential for the widespread application of RNAi in vivo. The integration of EphA2 siRNA into neutral liposomes, which, in animal studies, provides a highly effective method of lowering tumour EphA2 expression and anticancer action, either alone or with increased activity when paired with paclitaxel, is one example of how this is being addressed. Future design of nanoparticles that preferentially aggregate at the tumour site and, if loaded with medicine, convey their cargo directly to the tumour, may be made possible by the aberrant nature of the tumor's vasculature. The utilisation of pH-sensitive liposomes, cell-penetrating proteins and peptides, and immunoliposomes targeting intracellular antigens is also being developed for Intracellular Targeted Medication Delivery. Delivery methods to intracellular targets, such as the nucleus for gene therapy agents and the mitochondrion for pro-apoptotic medications and pharmaceuticals that target the mitochondrial genome, are also being developed.